Astrocytes are star-shaped glial cells that constitute the most abundant cell type in the mammalian brain. These multifaceted cells are essential for neuronal function, synaptic transmission, metabolic support, and maintenance of brain homeostasis. In neurodegenerative diseases, astrocytes undergo dramatic morphological and functional changes collectively termed "reactive astrocytosis," which can be both protective and detrimental to neuronal survival [1][2]. Understanding the complex roles of astrocytes in neurodegeneration is critical for developing therapeutic strategies that enhance their neuroprotective functions while minimizing their potential contributions to disease progression.
The traditional view of astrocytes as passive support cells has been dramatically revised over the past two decades. Modern neuroscience recognizes astrocytes as active participants in neural circuits, actively modulating synaptic transmission, releasing gliotransmitters, and responding to neuronal activity in sophisticated ways [3]. This active role means that astrocyte dysfunction can directly contribute to neurodegeneration through multiple mechanisms.
¶ Morphology and Classification
Astrocytes exhibit remarkable morphological diversity that correlates with their regional distribution and functional specialization:
Protoplasmic astrocytes are found primarily in gray matter, particularly the cerebral cortex. These cells extend numerous fine processes that ensheath synapses and blood vessels, creating the tripartite synapse architecture where astrocytes occupy a central position in modulating synaptic communication [4]. A single protoplasmic astrocyte can ensheath approximately 100,000 to 1 million synapses in the human brain, making them ideally positioned to regulate neural circuit function.
Fibrous astrocytes predominate in white matter and the spinal cord. These cells have fewer, longer processes that primarily contact nodes of Ranvier and blood vessels. Their morphology reflects their roles in maintaining axonal integrity and facilitating metabolism in white matter tracts [5].
Bergmann glia are specialized astrocytes in the cerebellar cortex that guide neuronal migration during development and maintain the molecular layer architecture. Their radial processes extend from the Purkinje cell layer to the pial surface, creating a scaffold for dendritic development [6].
Radial glia serve as neural progenitors during development and can give rise to new neurons in specific brain regions in the adult brain, including the subventricular zone and hippocampal subgranular zone [7].
Velate astrocytes are found in the cerebellum and olfactory bulb, with morphology adapted to their specific regional functions.
Astrocytes express a rich array of molecules that define their functions:
Glial fibrillary acidic protein (GFAP) is the canonical astrocytic marker used to identify and study astrocytes. GFAP expression increases dramatically during reactive astrocytosis, making it a useful biomarker for astrocyte activation in disease states [1]. However, not all astrocytes express high levels of GFAP, and its expression varies with brain region and developmental stage.
Glutamate transporters (EAAT1/GLAST and EAAT2/GLT-1) are responsible for the vast majority of glutamate uptake from the synaptic cleft. EAAT2/GLT-1 is the predominant transporter, responsible for approximately 90% of glutamate clearance in the forebrain [8]. Dysfunction of these transporters leads to excitotoxic neuronal death.
Aquaporin-4 (AQP4) is the primary water channel in astrocytes, concentrated at perivascular end-feet where it facilitates water movement between the brain parenchyma and blood vessels. AQP4 is essential for cerebral water homeostasis and is dysregulated in various neurological conditions [9].
S100β is a calcium-binding protein secreted by astrocytes that has both intracellular and extracellular functions. At low concentrations, S100β has neurotrophic effects, while elevated levels, as occur in reactive astrocytosis, may contribute to neuroinflammation and neurodegeneration [10].
Aldehyde dehydrogenase 1L1 (ALDH1L1) is a metabolic enzyme that serves as a specific astrocytic marker and is involved in one-carbon metabolism, linking astrocyte function to nucleotide synthesis and methylation reactions [11].
Tripartite synapse architecture describes the physical arrangement where astrocyte processes ensheath pre- and post-synaptic elements, allowing astrocytes to sense and modulate synaptic activity [4]. This structure enables:
- Detection of synaptic activity through neurotransmitter spillover
- Modulation of synaptic transmission through gliotransmitter release
- Regulation of extracellular ion and neurotransmitter concentrations
- Coordination of neural network activity
Gliotransmitters released by astrocytes include:
- Glutamate - modulates NMDA and AMPA receptor activity
- D-serine - co-agonist for NMDA receptors, essential for LTP
- ATP/adenosine - modulates presynaptic release probability
- GABA - can be released and activate GABA-B receptors
- Interleukin-6 and other cytokines - modulate synaptic plasticity
Metabolic coupling between astrocytes and neurons is essential for brain energy metabolism:
- Astrocytes take up glucose from blood vessels via GLUT1
- Glycolysis in astrocytes produces lactate
- Lactate is transported to neurons as an energy substrate
- The astrocyte-neuron lactate shuttle supports high neuronal activity [12]
In Alzheimer's disease, astrocytes undergo significant changes that both respond to and contribute to pathology:
Reactive astrocytosis is a hallmark of AD brain, characterized by:
- GFAP upregulation and hypertrophy of astrocyte processes
- Proliferation of astrocytes around amyloid plaques
- Formation of a "glial scar" in advanced disease stages
- Altered expression of ion channels and receptors [1]
Impaired glutamate clearance in AD results from:
- Downregulation and dysfunction of EAAT1/2 transporters
- Oxidative stress damaging transporter function
- Redistribution of transporters from processes to soma
- This leads to excitotoxic damage to cortical neurons [8]
Aβ metabolism interactions between astrocytes and amyloid:
- Astrocytes can uptake and degrade Aβ through receptor-mediated endocytosis
- Astrocyte-derived Apolipoprotein E (ApoE) influences Aβ aggregation and clearance
- Reactive astrocytes upregulate Aβ-degrading enzymes (neprilysin, IDE)
- However, chronic exposure impairs astrocyte function [13]
Lipid metabolism alterations in astrocytes affect:
- Cholesterol homeostasis and ApoE secretion
- Myelin maintenance in white matter
- Formation of lipid droplets in AD brain
- These changes may accelerate neurodegeneration [14]
Calcium dysregulation in astrocytes:
- Aβ stimulates abnormal calcium oscillations in astrocytes
- Elevated calcium triggers inappropriate gliotransmitter release
- This can cause synaptic dysfunction and inflammation
- Calcium waves propagate between astrocytes, spreading dysfunction [15]
Astrocytes play complex roles in PD pathogenesis:
α-Synuclein interactions with astrocytes:
- Astrocytes can internalize extracellular α-synuclein
- Aggregated α-synuclein accumulates in astrocytes in PD brain
- This triggers inflammatory responses and astrocyte dysfunction
- Astrocyte-mediated spread may contribute to disease progression [16]
Dopamine metabolism effects on astrocytes:
- Astrocytes metabolize dopamine through MAO-B
- Toxic dopamine oxidation products can accumulate
- Astrocyte dysfunction may alter dopamine clearance
- This contributes to extracellular dopamine dysregulation [17]
Neuroinflammatory responses in PD:
- Astrocytes produce pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
- Chemokine secretion attracts microglia to sites of injury
- Chronic inflammation impairs astrocyte support functions
- The inflammatory environment promotes further α-synuclein aggregation [18]
Astrocyte dysfunction is a major contributor to motor neuron degeneration in ALS:
Excitotoxicity from astrocyte dysfunction:
- Reduced EAAT2 (GLT-1) expression in ALS motor cortex and spinal cord
- Impaired glutamate uptake leads to motor neuron excitotoxicity
- Mutations in SOD1 astrocytes cause non-cell-autonomous motor neuron death
- Astrocyte-specific gene therapies show promise in preclinical models [19]
Metabolic support deficits:
- Impaired lactate production and transport
- Reduced metabolic coupling to motor neurons
- Mitochondrial dysfunction in astrocytes
- These changes reduce motor neuron energy supply [20]
Inflammatory signaling in ALS astrocytes:
- Upregulation of NF-κB and inflammatory gene expression
- Secretion of toxic factors that harm motor neurons
- Failure of normal trophic factor support
- Therapeutic targeting of astrocyte inflammation is under investigation [21]
In MS, astrocytes contribute to both demyelination and repair:
Pro-inflammatory roles:
- Release of cytokines that recruit immune cells
- Expression of adhesion molecules that facilitate immune cell infiltration
- Production of reactive oxygen and nitrogen species
- Astrocyte-derived matrix metalloproteinases that degrade the blood-brain barrier [22]
Remyelination support:
- secretion of trophic factors supporting oligodendrocyte precursor cells
- Formation of glial scars that can be permissive or inhibitory
- Remyelination failure in chronic MS may involve astrocyte dysfunction [23]
Enhancing glutamate uptake strategies:
- EAAT2/GLT-1 upregulators (e.g., ceftriaxone)
- Gene therapy to increase transporter expression
- Small molecules that enhance transporter trafficking
- These approaches aim to reduce excitotoxic neuronal death [8]
Modulating astrocyte reactivity:
- Anti-inflammatory drugs targeting astrocyte activation
- Inhibition of A1 neurotoxic astrocyte polarization
- Promotion of A2 neuroprotective phenotype
- BMP signaling modulation to influence astrocyte phenotype [24]
Metabolic support enhancement:
- Lactate supplementation or metabolic coupling enhancement
- Glucose transporter modulators
- Mitochondrial function enhancers
- Supporting astrocyte energy metabolism indirectly protects neurons [12]
Trophic factor delivery:
- Astrocytes produce BDNF, GDNF, and other neurotrophic factors
- Enhancing astrocyte trophic support is neuroprotective
- Gene therapy approaches to increase astrocyte trophic factor production
- These strategies support neuron survival and function [25]
- Pekny et al., Astrocytes in neurodegeneration (2019)
- Ben Haim & Rowitch, Functional diversity of astrocytes (2017)
- Araque et al., Gliotransmitters in synaptic transmission (1999)
- Perea et al., Tripartite synapses (2014)
- Miller & Raff, Fibrous astrocytes (1984)
- Rakic, Bergmann glia development (1971)
- Götz & Huttner, Radial glia progenitors (2005)
- Rothstein et al., Glutamate transporters in ALS (1996)
- Nielsen et al., Aquaporin-4 in brain (1997)
- Van Eldik & Wainwright, S100β in neurodegeneration (2003)
- Cahoy et al., Astrocyte transcriptome (2008)
- Pellerin & Magistretti, Lactate shuttle (1994)
- Wyss-Coray et al., Astrocyte ApoE in AD (2003)
- Ishii & Ikeshita, Astrocyte lipid metabolism in AD (2020)
- Verkhratsky et al., Astrocyte calcium signaling (2012)
- Braak et al., α-Synuclein in astrocytes (2003)
- Stansley et al., Astrocytes in PD (2019)
- Gao et al., Neuroinflammation in PD (2011)
- Nagai et al., Astrocytes in ALS (2007)
- Schildge et al., Astrocyte metabolism in neurodegeneration (2013)
- Phatnani et al., ALS astrocyte transcriptome (2013)
- Nair et al., Astrocytes in MS (2008)
- Franklin & ffrench-Constant, Remyelination in MS (2008)
- Liddelow et al., Neurotoxic A1 astrocytes (2017)
- Bankston et al., Astrocyte neurotrophic support (2013)